Psma-Hbed-Cc
Positron-Emission Tomography
First Affiliated Hospital of Fujian Medical UniversityradiopharmaceuticalEarly Phase 1Dormant
C
39/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 24/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Positron-Emission Tomography cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Zirconium Zr 89 Crefmirlimab Berdoxam ImaginAb, Inc. | Phase 2 | B |
Same molecule, other indications
Psma-Hbed-Cc is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →